Q-omics provides the consensus-scored P2RX3 profile across patient tissues and cancer cell-line models. P2RX3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, P2RX3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, P2RX3 RNA expression shows 14,365 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where P2RX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for P2RX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes P2RX3 survival associations across molecular data types. P2RX3 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible P2RX3 RNA expression–survival associations across cancer types. High P2RX3 expression shows unfavorable associations in KIRP, THCA and SKCM, but favorable associations in LUAD, UCS and CHOL. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for P2RX3 RNA expression.
This table summarizes P2RX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for P2RX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. P2RX3 shows lower tumor expression in CHOL, LIHC and THCA and higher tumor expression in KIRC, PAAD and LUAD. The KIRC box plot shows higher P2RX3 RNA expression in tumor versus normal tissue (log2 FC = +0.264, t-test p < 0.001).
This table shows molecular features associated with P2RX3 in patient tissues and cancer cell lines. In patient samples, P2RX3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, P2RX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
